1世界反興奮劑條例禁用清單2026年2TABLEOFCONTENTS infertility(female),polycysticovariansyndr3本類別某些物質(zhì)可能存在但不限于治療如心力衰竭、M1-M2-M3hyperactivitydisorders(ADHD), usedforthetreatmentofe.g.allergy,anaphylaxis,as4 56performance.”依照《條例》條款4.2.2，“為適用第10條，除《禁用清單》中明確列出以否則任何禁用方法均不屬于特定方法”。根據(jù)該條款釋義，“條款4.2.2中確定的這些物質(zhì)和方法更容易被運(yùn)動(dòng)員服用或使用，用于提高運(yùn)動(dòng)能力以外的其他目的?！?THC).依照《條例》條款4.2.3，濫用物質(zhì)是指經(jīng)常在體育運(yùn)動(dòng)以外的社會(huì)環(huán)境中），甲基亞甲二氧基苯丙胺[MDMA/亞甲基二氧甲基苯丙胺（中文注：搖頭丸主要成7S0.NON-APPROVEDSUBSTANCES未獲批準(zhǔn)的物質(zhì)governmentalregulator），(e.g.reldesemtivandtirasemtiv).蘭尼堿受體-1-鈣穩(wěn)定蛋白復(fù)合物穩(wěn)定劑（阿諾堿受體-1-鈣穩(wěn)定蛋白復(fù)合物穩(wěn)定劑）[例如：S-107和S48168（ARM210）]和肌鈣蛋白激活劑（例如：瑞地生替8S1.ANABOLICAGENTS蛋白同化制劑AnabolicagentsareprohibitWhenadministeredexogenously,includi4-Hydroxytestosterone(4,17β-dihydroxyandr5-Androstenedione(androst-5-e9Androstanolone(5α-dihydrotestosterone,17βAndrostenedione(androst-4-ene-3,17-dionBoldione(androsta-1,4-diene-3,17-diDanazol([1,2]oxazolo[4',5':2,3]pregna-4-en-2Dehydrochlormethyltestosterone(4-chloro-17β-hydDesoxymethyltestosterone(17α-methyDimethandrolone(7α,11Epiandrosterone(3β-hydroxyEpi-dihydrotestosterone(17β-hydroxEthylestrenol(19-norpregnFurazabol(17α-methyl[1,2,5]oxadiazolo[3Metandienone(17β-hydroxy-17α-methylandrostaMethasterone(17β-hydroxMethyldienolone(17β-hydroxy-17α-methylestraMethylnortestosterone(17β-hydroxy-17α-methylMetribolone(methyltrienolone,17β-hydroxy-17α-methylNandrolone(19-nortestosteronNorclostebol(4-chloro-17β-ol-estr-4-Prasterone(dehydroepiandrosteronProstanozol(17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazoα-androstane);Tetrahydrogestrinone(17-hydroxy-18a-homo-19-nor-17α-prTrenbolone(17β-hydroxyestr-4,9,11Trestolone(7α-Methyl-19-nortestoClenbuterol,osilodrostat,ractopamine,selectiveandrogenmodulators[SARMs,e.g.andarine,enobosarm(ostarinLGD-4033(ligandrol),RAD140,S-23andYK-11]andarine、依諾波沙（ostarine）、LGD-4033（ligandrol）、RAS2.PEPTIDEHORMONES,GROWTHFACTORS,RELATEDSUBSTANCES,ANDMIMETICS肽類激素、生長(zhǎng)因子、相關(guān)物質(zhì)和模擬物S2.1.1Erythropoietinreceptoragonists,e.g.darbepoeerythropoietins(EPO);EPO-basedconstructs[e.g.EPO-Fc,methoxytheirconstructs(e.g.CNTO-530,peginesatide,pegmolesatide).促紅素受體激動(dòng)劑類，例如：達(dá)促紅素類（dEPO）；促紅素類）；基于促紅素類分子結(jié)構(gòu)的構(gòu)建物[例如：促紅素S2.1.2Hypoxia-induciblefactor(HIF)activatingagents,e.g.cdaprodustat(GSK1278863);IOX(FG-4592);vadadustat(A轉(zhuǎn)化生長(zhǎng)因子-β（TGF-β)信號(hào)傳導(dǎo)抑制劑，例如：羅特西普；索特西?gonadotrophin-releasinghoragonistanalogues(e.g.buserelin,deslorelin,histrelin,leuprorelin,nafa），瑞林）生長(zhǎng)激素釋放肽-1（GHRP-1）、生長(zhǎng)激素釋生長(zhǎng)激素釋放肽-5（GHRP-5）和生長(zhǎng)激素釋放肽-6（FibroblastgrowthfactorsHepatocytegrowthfactor(Mechanogrowthfactors(MGFPlatelet-derivedgrowthfactorVascularendothelialtendonorligamentproteinsynthesis/degS3.BETA-2AGONISTS2激動(dòng)劑Tretoquinol(trimetoTulobuterol;）：）：S4.HORMONEANDMETABOLICMODULATORS激素及代謝調(diào)節(jié)劑Thefollowinghormoneandmetabolicmodulatorsareprohi2-苯基苯并[h]色烯-4-酮(α-萘黃酮；7,8-苯并黃酮）4-Androstene-3,6,17trionAndrosta-1,4,6-triene-3,17-dione(androstatrienedionAndrosta-3,5-diene-7,17-dione(arimistan雄甾-3,5-二烯-7,17-二酮（a5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiaagonists,e.g.2-(2-methyl-4-((4-methyl-2-(4-(trifluoroml)thiazol-5-yl)methylthio)phenoxy)ace?Rev-erbɑagon?Rev-erb核受體激動(dòng)劑，例如：SR胰島素類以及胰島素模擬物類,例如：S51S5.DIURETICSANDMASKINGAGENTS利尿劑和掩蔽劑?Acetazolamide;amiloride;bumetanetacrynicacid;furosemide;inthiazides,e.g.bendroflumethiazide,chlor帕胺；美托拉宗；螺內(nèi)酯；噻嗪類，例如：卞氟噻嗪、氯噻嗪和氫氯噻嗪；托），Albumin,dextran,hydroxyethylstarbiologicaleffect(s).?Drospirenone;pamabrom;andtopicalophthalmicadmincarbonicanhydraseinhibitors(e.g.dorzolamidthresholdlimits:formoterol,（除了碳酸酐酶抑制劑的眼部局部給藥，或苯賴加壓素在牙科麻醉中的局部給堿、麻黃堿、甲基麻黃堿和偽麻黃堿，將視為陽(yáng)性檢測(cè)結(jié)果（AAF），除非運(yùn)動(dòng)PROHIBITEDMETHODS禁用方法allogenic(homologous)orheterologousbPerfluorochemicals;efaproxiral(RSR13);voxelotorandmohaemoglobinproducts,e.g.haemoglobin-basedbloodsubstitumicroencapsulatedhaemoglobinproducts,excludingsupplemen乙丙昔羅（RSR13）；伏塞洛托和經(jīng)修飾的血紅蛋白制劑，例如以血紅蛋白monoxide,unlessperformedasadiag篡改或企圖篡改以改變?cè)谂d奮劑管制過(guò)程中采集到使用可能通過(guò)任何機(jī)制改變基因組序列和/或改變基因表達(dá)的核酸或核酸類(e.g.nucleiandorganS6.STIMULANTS刺激劑methylenedioxymethamphetamine(MDMA/“ecstaFladrafinil(2-[Bis[4-fluorophenyl)methylsulfinyl]-N-hydroxyaFonturacetam[4-phenylpiracetam(carphe芳妥西坦[4-苯基吡拉西坦（卡非多）]Prolintane;2-phenylpropan-1-amine(?-methylphenylet4-甲基己烷-2-胺（1，3-二甲基戊胺CathinoneanditsanalogDimetamfetamine(dimethylamphetaEpinephrine****(adreHydroxyamfetamine(parahydroxyamphetamMethylenedioxymethamphetamiMethylnaphthidate[(±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl萘乙酸甲酯[(±)-甲基-2-(萘-2-基)-2-(Octodrine(1,5-dimethylheOxilofrine(methylsyTenamfetamine(methylenedioxyamphebiologicaleffect(s).?Imidazolinederivativesfordermatolouse(e.g.brimonidine,clonazoline,fenoxazoline,indanazoline,naphaz,oxymetazoline,tetryzoline,tramazoline,xylometazoline)andtho*Bupropion,caffeine,nicotine,phenylephrine,phenylpropa**Cathine(d-norpseudoephedrine)a去甲偽麻黃堿(d-去甲偽麻黃堿)及其l-異構(gòu)體：尿中濃麻黃堿或甲基麻黃堿：任一物質(zhì)的尿中濃度超過(guò)nasal,ophthalmologic,orco-administrationwithlocalanaeS7.NARCOTICS麻醉劑whererelevant,areprohibiteTramadol;S8.CANNABINOIDS大麻（酚）類Allnaturalandsynth?Incannabis(hashish,?NaturalandsyntheS9.GLUCOCORTICOIDS糖皮質(zhì)激素oral[includingoromucosal(e.g.buccal,gingival,sublingual)]orOtherroutesofadministration(includinginhanotprohibitedwhenusedwithintheP1.BETA-BLOCKERS射擊（ISSF，國(guó)際射擊聯(lián)合會(huì)，IPC，國(guó)際?Underwatersports(CMAS)水下運(yùn)動(dòng)（CMAS，世界水下運(yùn)動(dòng)聯(lián)合會(huì)）*包括Thefollowingsubstphenylpropanolamine,pipradrolandsyndihydrocodeine,hydrocodonesport.”*《世界反興奮劑條例》（條款4.5）規(guī)定：“WADA應(yīng)當(dāng)與物質(zhì)，以便發(fā)現(xiàn)其在體育運(yùn)動(dòng)中潛在的濫用方式?！眑2-Phenylbenzo[h]chromen-4-one,alsoknownasɑ-napPharmacometric-basedevaluationofsalimplicationsfordopingcontrol.Submittedforpl新增2-苯基苯并[h]色烯-4-酮(α-萘黃酮；7,8-苯并黃酮），作為芳香酶l5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[l新增5-N,6-N-雙(2-氟苯基)-[1,2,5]二唑并[3,4-b]吡嗪-5,6-二胺，也叫做BAM15，作為腺苷酸活化蛋白激酶（AMPK）激動(dòng)劑的示例。該合成物質(zhì)andrelatedpr